DEEJ(000423)

Search documents
东阿阿胶(000423) - 监事会关于第一期限制性股票激励计划首次授予激励对象名单(授予日)的核查意见
2025-06-18 11:00
首次授予激励对象名单(授予日)的核查意见 本公司及监事会全体成员保证信息披露的内容真实、准确和完整,没有 虚假记载、误导性陈述或重大遗漏。 2025 年 6 月 18 日,东阿阿胶股份有限公司(以下简称"公司")第十一届 监事会第八次会议审议通过了《关于调整第一期限制性股票激励计划相关事项的 议案》《关于向第一期限制性股票激励计划激励对象首次授予限制性股票的议案》。 证券代码:000423 证券简称:东阿阿胶 公告编号:2025-39 东阿阿胶股份有限公司 监事会关于第一期限制性股票激励计划 (2)最近 12 个月内被中国证监会及其派出机构认定为不适当人选; (3)最近 12 个月内因重大违法违规行为被中国证监会及其派出机构行政 处罚或者采取市场禁入措施; (4)具有《公司法》规定的不得担任公司董事、高级管理人员情形的; 公司监事会依据《中华人民共和国公司法》(以下简称《公司法》)、《中 华人民共和国证券法》(以下简称《证券法》)、《上市公司股权激励管理办法》 (以下简称《管理办法》)等有关规定,对公司第一期限制性股票激励计划(以 下简称"本次激励计划")首次授予激励对象名单(授予日)进行了核查,发表 核查意 ...
东阿阿胶(000423) - 第十一届监事会第八次会议决议公告
2025-06-18 11:00
3.会议应出席会议监事 5 人,实际出席会议监事 5 人。 4.本次监事会会议的召开,符合有关法律、行政法规、部门规章、规范性 文件和公司章程等规定。 证券代码:000423 证券简称:东阿阿胶 公告编号:2025-36 东阿阿胶股份有限公司 第十一届监事会第八次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确和完整,没有 虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 1.东阿阿胶股份有限公司(以下简称"公司")第十一届监事会第八次会 议,于 2025 年 6 月 15 日以邮件方式发出会议通知。 2.本次监事会会议,于 2025 年 6 月 18 日以通讯表决方式召开。 2.《关于向第一期限制性股票激励计划激励对象首次授予限制性股票的议案》 经审议,监事会认为:董事会确定的首次授予日符合《管理办法》及本激励 计划关于授予日的相关规定。公司和激励对象均未发生不得授予限制性股票的情 形,获授限制性股票的条件已经成就。首次授予的激励对象,符合相关法律法规、 部门规章和规范性文件所规定的条件,符合公司本激励计划确定的激励对象范围, 其作为本激励计划激励对象的主体资格合法、有效。 同意以 ...
东阿阿胶(000423) - 第十一届董事会第九次会议决议公告
2025-06-18 11:00
证券代码:000423 证券简称:东阿阿胶 公告编号:2025-35 东阿阿胶股份有限公司 第十一届董事会第九次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整,没有 虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1.东阿阿胶股份有限公司(以下简称"公司")第十一届董事会第九次会议, 于 2025 年 6 月 15 日以邮件方式发出会议通知。 2.本次董事会会议,于 2025 年 6 月 18 日以通讯表决方式召开。 3.会议应出席会议董事 9 人,实际出席会议董事 9 人。 4.本次董事会会议的召开,符合有关法律、行政法规、部门规章、规范性文 件和公司章程等规定。 二、董事会会议审议情况 本次会议审议并通过了以下议案: 1.《关于调整董事会部分专门委员会委员的议案》 会议同意对公司第十一届董事会战略委员会、审计委员会及薪酬与考核委员 会组成人员进行补充调整,调整后的上述委员会成员名单如下: (1)战略委员会 2.《关于修改<总裁工作细则>的议案》 程杰(主任委员)、果德安、王小跃、于晓辉、孙金妮 (2)审计委员会 文光伟(主任委员)、果德安、孙晓波、徐培清、于晓辉 (3)薪 ...
第十六届上市公司投资者关系管理天马奖正式揭晓!
证券时报· 2025-06-14 00:13
Core Viewpoint - The article discusses the 16th Investor Relations Management Forum held in Yangzhou, where the winners of the Tianma Award for outstanding investor relations management were announced, highlighting the importance of effective communication between listed companies and their investors [1][2]. Group 1: Tianma Award Overview - The Tianma Award, organized by the Securities Times, is one of the earliest evaluation activities focused on investor relations management in China's capital market [2]. - The award aims to enhance the investor relations management level of listed companies and recognize those that excel in this field [2]. Group 2: Award Categories - Six categories of awards were presented: 1. Investor Relations Management Tianma Award 2. Outstanding Secretary of the Board Award 3. Excellent Team Award 4. Shareholder Return Award 5. Innovative Practice Award 6. Hong Kong Stock Market Investor Relations Management Tianma Award [2]. Group 3: Award Winners - A list of companies that received awards includes notable names such as BYD (002594), Mindray Medical (300760), and Yunnan Copper (000878) among others [3][4][5][6][8][9]. - The awards recognize companies across various sectors, indicating a broad commitment to improving investor relations [3][4][5][6][8][9]. Group 4: Notable Individuals - The article also highlights the names of secretaries of the board from awarded companies, showcasing the individuals who play a crucial role in investor relations [8][10]. - This recognition emphasizes the importance of leadership in fostering effective communication with investors [8][10]. Group 5: Hong Kong Stock Market Awards - The article lists the winners of the Hong Kong Stock Market Investor Relations Management Tianma Award, including companies like China Merchants Industry Holdings (1919.HK) and Kuaishou Technology (1024.HK) [19]. - This segment illustrates the growing recognition of investor relations practices in the Hong Kong market [19].
中药行业2025年半年度策略暨中报前瞻:药中银行,内需为王
ZHESHANG SECURITIES· 2025-06-12 09:50
Core Viewpoints - The Chinese medicine industry is expected to see a performance turning point, with significant improvements in revenue and profit growth anticipated in Q2 2025 compared to Q1 2025, and continued growth in H2 2025 [3][7] - The industry exhibits characteristics similar to the banking sector, including high cash reserves, substantial dividends, and low profit volatility, with minimal impact from overseas situations [3][7] Key Indicators Tracking - Influenza data has stabilized, reducing revenue growth pressure on companies [11] - The price index of Chinese medicinal materials has declined, which is expected to alleviate gross margin pressure [13] - Institutional holdings are low, with the proportion of fund holdings in the Chinese medicine sector dropping to 0.46% as of Q1 2025, indicating potential for increased investment interest under favorable tariff policies in the U.S. [18] - The sector's valuation is slightly above the average level since 2021, with a TTM price-to-earnings ratio of 27.78x as of June 12, 2025 [21] Investment Recommendations - Companies with stable and rapid profit growth and new consumption logic include Dong'e Ejiao and Lingrui Pharmaceutical, with a focus on Mayinglong [30] - High-barrier, large-cap state-owned enterprises with light institutional positions include Tianshili, Yunnan Baiyao, Tongrentang, and Pianzaihuang [30][6] Mid-Year Performance Outlook - The report provides a forecast for the first half of 2025, indicating expected year-on-year growth rates for various companies, with Dong'e Ejiao projected to grow by approximately 20% in Q2 2025 [34]
山东上市公司4月传播影响力指数均值微涨,谁被挤出TOP10?
Sou Hu Cai Jing· 2025-06-11 06:38
Core Insights - The overall brand communication effectiveness of Shandong listed companies showed improvement in April 2025, with an average INC index of 588.49, reflecting a 0.43% increase from March [1][3] - The company with the highest increase in ranking was Zhongchuang Logistics Co., Ltd., which rose by 156 positions, while Zhiyang Innovation Technology Co., Ltd. experienced the largest drop, falling by 132 positions [1] INC Index Overview - The INC index, or Internet Communication Influence Index, serves as a quantitative evaluation system for brand communication effectiveness in the digital age [2] - The index evaluates dimensions such as communication breadth, heat, online attention, and official website presentation [2] Industry Level Analysis - The average INC index of 588.49 indicates that most brands in the industry are maturing and gaining more attention, with both brand voice and social concern on the rise [3] - The skewness coefficient of the INC index is 0.77, indicating a moderate right-skewed distribution, where a few units exhibit outstanding communication influence, enhancing the overall industry INC level [3] Communication Breadth Analysis - The average communication breadth index for April was 2.73, categorized as "standard level" [5] - Eight companies achieved the highest level (5), including Qingdao Beer Co., Ltd. and Haier Smart Home Co., Ltd. [5] - A total of 68 companies reached level 4 ("upgraded level"), while 212 companies were at level 3 ("standard level") [5] Communication Heat Analysis - The average communication heat index was 2.36, also at the "standard level" [6] - Five companies reached the highest level (5), including Qingdao Beer Co., Ltd. and Haier Smart Home Co., Ltd. [7] - A total of 50 companies achieved level 4, indicating strong activity and high information engagement [7][8] Online Attention Analysis - The average online attention index was 1.6, categorized as "regional attention" [9] - 107 companies reached level 3 or above ("national attention"), including Qingdao Beer Co., Ltd. and Haier Smart Home Co., Ltd. [10] - 114 companies were at the lowest level ("sporadic attention"), indicating low brand awareness [10] Official Website Presentation Analysis - The average official website presentation index was 1.08, below the "standard level" [11] - Two companies achieved the highest level (5), including Haier Smart Home Co., Ltd. [12] - A total of 176 companies were at the lowest level ("deep water level"), indicating poor website visibility [12]
6月3日中欧医疗健康混合C净值增长0.96%,今年来累计上涨8.66%
Sou Hu Cai Jing· 2025-06-03 11:33
Group 1 - The core viewpoint of the news is the performance and holdings of the China Europe Medical Health Mixed Fund C, which has shown positive growth in its net value and returns over various time frames [1] - As of June 3, 2025, the latest net value of the fund is 1.6391 yuan, with a growth of 0.96%. The fund's return over the past month is 7.34%, ranking 224 out of 4690 in its category. Over the past three months, the return is 7.88%, ranking 461 out of 4620, and since the beginning of the year, the return is 8.66%, ranking 977 out of 4568 [1] - The top ten stock holdings of the fund account for a total of 55.30%, with significant positions in companies such as Heng Rui Pharmaceutical (10.60%), WuXi AppTec (9.95%), and Mindray Medical (5.21%) [1] Group 2 - The China Europe Medical Health Mixed Fund C was established on September 29, 2016, and as of March 31, 2025, it has a total scale of 15.566 billion yuan [1] - The fund manager, Ge Lan, has a background in biomedical engineering and has held various positions in research and fund management since joining China Europe Fund Management Company in October 2014 [2]
工业利润修复情况有待观察,500质量成长ETF(560500)盘中上涨
Sou Hu Cai Jing· 2025-05-28 02:42
Group 1 - The core viewpoint of the news highlights the performance of the CSI 500 Quality Growth Index and its constituent stocks, indicating a slight increase in the index and notable gains in specific stocks like Debang Co., Ltd. and Laofengxiang [1] - As of April 2025, the cumulative year-on-year revenue growth for industrial enterprises was 3.2%, while profit growth was 1.4%, showing a slight decline from previous values [1] - The CSI 500 Quality Growth ETF closely tracks the CSI 500 Quality Growth Index, which selects 100 companies with high profitability, sustainable earnings, and strong cash flow from the CSI 500 Index [2] Group 2 - The top ten weighted stocks in the CSI 500 Quality Growth Index account for 24.07% of the index, with notable companies including Chifeng Jilong Gold Mining and Ninebot [2] - The performance of the CSI 500 Quality Growth ETF is influenced by the underlying index, which reflects the profitability and growth potential of its constituent companies [2] - The analysis indicates that the impact of tariffs on profitability may be delayed, with uncertainties surrounding profit recovery due to low capacity utilization in the mid and downstream sectors [2]
5月27日中欧医疗健康混合C净值增长0.85%,近1个月累计上涨3.03%
Sou Hu Cai Jing· 2025-05-27 12:01
Group 1 - The core viewpoint of the news is the performance and holdings of the China Europe Medical Health Mixed Fund C, which has shown a recent net value increase and varying returns over different time frames [1] - As of May 27, 2025, the fund's latest net value is 1.5582 yuan, reflecting a growth of 0.85% [1] - The fund's one-month return is 3.03%, ranking 1106 out of 4652 in its category, while its six-month return is 0.23%, ranking 3299 out of 4496 [1] - Year-to-date, the fund has achieved a return of 2.43%, ranking 2140 out of 4544 [1] Group 2 - The top ten stock holdings of the fund account for a total of 55.30%, with significant positions in companies such as Heng Rui Pharmaceutical (10.60%), WuXi AppTec (9.95%), and Kanglong Chemical (6.24%) [1] - The fund was established on September 29, 2016, and as of March 31, 2025, it has a total scale of 15.566 billion yuan [1] - The fund manager, Ge Lan, has a background in biomedical engineering and has held various positions in research and fund management since joining China Europe Fund Management in 2014 [2]
5月26日中欧医疗健康混合A净值下跌1.60%,近3个月累计上涨0.39%
Sou Hu Cai Jing· 2025-05-26 13:08
Group 1 - The core viewpoint of the news is the performance and holdings of the China Europe Medical Health Mixed A Fund, which has seen a recent decline in net value and varying returns over different time frames [1] - As of May 26, 2025, the latest net value of the fund is 1.6119 yuan, reflecting a decrease of 1.60%. The fund's one-month return is 3.10%, six-month return is 0.62%, and year-to-date return is 2.75, with respective rankings of 937 out of 3909, 2718 out of 3796, and 1764 out of 3832 [1] - The top ten stock holdings of the fund account for a total of 55.30%, with significant positions in companies such as Heng Rui Pharmaceutical (10.60%), WuXi AppTec (9.95%), and Mindray Medical (5.21%) [1] Group 2 - The China Europe Medical Health Mixed A Fund was established on September 29, 2016, and as of March 31, 2025, it has a total scale of 15.613 billion yuan. The fund manager is Ms. Ge Lan [1] - Ms. Ge Lan has a background in biomedical engineering with a Ph.D. from Northwestern University and has held various research and fund management positions since joining China Europe Fund Management in October 2014 [2]